Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

(MedPage Today) -- Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and meaningful survival in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer...